J Natl Cancer Inst:全球乳腺癌治疗指南汇总分析:大多数指南不符合实际!

2021-01-28 MedSci原创 MedSci原创

乳腺癌(BC)是世界范围内女性发病率、死亡率和残疾的主要原因。

乳腺癌(BC)是世界范围内女性发病率、死亡率和残疾的主要原因。全球各地BC的治疗预后有很大的差异,这是多种因素混合导致的,包括获得治疗的机会。治疗标准可以改善治疗质量、提高存活率;因此,制定治疗标准应该是癌症控制规划的优先事项。

Dario等从文献的系统综述中提炼出了BC的治疗指南,对其发展过程、制定方法和建议进行了评估,并对国家资源分层进行了调查。选择卫生系统能力的衡量标准,以研究指南的适宜性。

最终,该分析共纳入了49个不同的BC治疗指南,其中大部分是英文版(n=23),这些指南多是欧美地区的中上收入和高收入国家制定的(n=39)。四分之一的指南(n=11)确定了资源分层方法,这些方法大多来自资源受限的情况。只有一半的指南达到了作者的性别平衡,10.2%的指南是基于多学科指导委员会。人们认识到资源适应方面需要付诸一些努力和寻找解决办法,主要是在低收入和中等收入国家。

总体而言,国家性指南在制定建议时似乎对当地卫生系统的能力不够了解,换言之,当地卫生系统做不到国家指南给出的建议治疗;放射治疗的可获得性可能是唯一例外一条。

本文通过对全球的BC治疗指南进行汇总分析发现,大多数指南推荐的标准治疗并不适用于实际情况。因此,开展制定合理的癌症治疗标准的研究是非常有必要的,同时还需要开发和传播适合资源的指南的新平台。

原始出处:

Trapani Dario,Yves Douillard Jean,Winer Eric P et al. The global landscape of treatment standards for breast cancer. J Natl Cancer Inst, 2021, https://doi.org/10.1093/jnci/djab011

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053580, encodeId=fdec2053580af, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Feb 21 21:01:11 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934928, encodeId=317d193492896, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Aug 03 21:01:11 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977598, encodeId=3bf519e75987b, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Oct 12 03:01:11 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884933, encodeId=dac3188493301, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 16 03:01:11 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950254, encodeId=1a53195025439, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jul 01 20:01:11 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921050, encodeId=29299210502c, content=赞👍🏻<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49f55457070, createdName=于璇, createdTime=Fri Jan 29 15:01:52 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921020, encodeId=5785921020b8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:37:18 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920895, encodeId=60dc92089510, content=好好学习天天向上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Fri Jan 29 02:53:56 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2053580, encodeId=fdec2053580af, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Feb 21 21:01:11 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934928, encodeId=317d193492896, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Aug 03 21:01:11 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977598, encodeId=3bf519e75987b, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Oct 12 03:01:11 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884933, encodeId=dac3188493301, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 16 03:01:11 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950254, encodeId=1a53195025439, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jul 01 20:01:11 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921050, encodeId=29299210502c, content=赞👍🏻<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49f55457070, createdName=于璇, createdTime=Fri Jan 29 15:01:52 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921020, encodeId=5785921020b8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:37:18 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920895, encodeId=60dc92089510, content=好好学习天天向上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Fri Jan 29 02:53:56 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2053580, encodeId=fdec2053580af, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Feb 21 21:01:11 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934928, encodeId=317d193492896, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Aug 03 21:01:11 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977598, encodeId=3bf519e75987b, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Oct 12 03:01:11 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884933, encodeId=dac3188493301, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 16 03:01:11 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950254, encodeId=1a53195025439, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jul 01 20:01:11 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921050, encodeId=29299210502c, content=赞👍🏻<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49f55457070, createdName=于璇, createdTime=Fri Jan 29 15:01:52 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921020, encodeId=5785921020b8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:37:18 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920895, encodeId=60dc92089510, content=好好学习天天向上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Fri Jan 29 02:53:56 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-10-12 drj2003
  4. [GetPortalCommentsPageByObjectIdResponse(id=2053580, encodeId=fdec2053580af, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Feb 21 21:01:11 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934928, encodeId=317d193492896, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Aug 03 21:01:11 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977598, encodeId=3bf519e75987b, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Oct 12 03:01:11 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884933, encodeId=dac3188493301, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 16 03:01:11 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950254, encodeId=1a53195025439, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jul 01 20:01:11 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921050, encodeId=29299210502c, content=赞👍🏻<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49f55457070, createdName=于璇, createdTime=Fri Jan 29 15:01:52 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921020, encodeId=5785921020b8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:37:18 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920895, encodeId=60dc92089510, content=好好学习天天向上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Fri Jan 29 02:53:56 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-07-16 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=2053580, encodeId=fdec2053580af, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Feb 21 21:01:11 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934928, encodeId=317d193492896, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Aug 03 21:01:11 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977598, encodeId=3bf519e75987b, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Oct 12 03:01:11 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884933, encodeId=dac3188493301, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 16 03:01:11 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950254, encodeId=1a53195025439, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jul 01 20:01:11 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921050, encodeId=29299210502c, content=赞👍🏻<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49f55457070, createdName=于璇, createdTime=Fri Jan 29 15:01:52 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921020, encodeId=5785921020b8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:37:18 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920895, encodeId=60dc92089510, content=好好学习天天向上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Fri Jan 29 02:53:56 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-07-01 qidongfanjian
  6. [GetPortalCommentsPageByObjectIdResponse(id=2053580, encodeId=fdec2053580af, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Feb 21 21:01:11 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934928, encodeId=317d193492896, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Aug 03 21:01:11 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977598, encodeId=3bf519e75987b, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Oct 12 03:01:11 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884933, encodeId=dac3188493301, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 16 03:01:11 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950254, encodeId=1a53195025439, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jul 01 20:01:11 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921050, encodeId=29299210502c, content=赞👍🏻<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49f55457070, createdName=于璇, createdTime=Fri Jan 29 15:01:52 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921020, encodeId=5785921020b8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:37:18 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920895, encodeId=60dc92089510, content=好好学习天天向上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Fri Jan 29 02:53:56 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-29 于璇

    赞👍🏻#学习#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2053580, encodeId=fdec2053580af, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Feb 21 21:01:11 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934928, encodeId=317d193492896, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Aug 03 21:01:11 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977598, encodeId=3bf519e75987b, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Oct 12 03:01:11 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884933, encodeId=dac3188493301, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 16 03:01:11 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950254, encodeId=1a53195025439, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jul 01 20:01:11 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921050, encodeId=29299210502c, content=赞👍🏻<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49f55457070, createdName=于璇, createdTime=Fri Jan 29 15:01:52 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921020, encodeId=5785921020b8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:37:18 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920895, encodeId=60dc92089510, content=好好学习天天向上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Fri Jan 29 02:53:56 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-29 精气神

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2053580, encodeId=fdec2053580af, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Feb 21 21:01:11 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1934928, encodeId=317d193492896, content=<a href='/topic/show?id=1072646328c' target=_blank style='color:#2F92EE;'>#治疗指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64632, encryptionId=1072646328c, topicName=治疗指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6732482, createdName=w984445tii, createdTime=Tue Aug 03 21:01:11 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977598, encodeId=3bf519e75987b, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Oct 12 03:01:11 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884933, encodeId=dac3188493301, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jul 16 03:01:11 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950254, encodeId=1a53195025439, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jul 01 20:01:11 CST 2021, time=2021-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921050, encodeId=29299210502c, content=赞👍🏻<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49f55457070, createdName=于璇, createdTime=Fri Jan 29 15:01:52 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921020, encodeId=5785921020b8, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/11/07/32f6eeca95f16df602e2fe81e7416090.jpg, createdBy=ddb32421444, createdName=精气神, createdTime=Fri Jan 29 13:37:18 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=920895, encodeId=60dc92089510, content=好好学习天天向上!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Fri Jan 29 02:53:56 CST 2021, time=2021-01-29, status=1, ipAttribution=)]
    2021-01-29 用户被禁用

    好好学习天天向上!

    0

相关资讯

Nat Med:转移性乳腺癌中Durvalumab与维持化疗的疗效比较

乳腺癌包括三种主要的分子亚型,即Her2过表达、激素受体阳性(HR+)和三阴性乳腺癌(TNBC)。 HR+和Her2过表达的转移性乳腺癌(mBCs)目前可通过靶向疗法(内分泌疗法,CDK4/6抑制剂和

Nat Med:雄激素受体:雌激素受体阳性乳腺癌的抑癌因子

在乳腺的发育过程中,雌激素(ER)能够刺激青春期后乳腺的生长,相反的,雄激素(AR)则会抑制该发育过程。

Annl Oncol:ctDNA状态对乳腺癌治疗缓解和复发的预测能力

新辅助化疗(NAC)后患者获得病理完全缓解(pCR)与后续获得良好的预后密切相关。本研究旨在评估连续循环肿瘤DNA(ctDNA)监测用于预测pCR和转移复发风险的实用性。

Br J Cancer:靶向细胞自噬作用改善乳腺癌治疗中PARP抑制剂耐药性的产生

乳腺癌作为全球女性中最常见的癌症之一,也是癌症相关死亡的主要原因。

Nat Commun:限制进食时间可以降低绝经后乳腺癌的概率

TRF在没有限制卡路里或减轻体重的情况下,抑制了两个模型中肥胖增强的乳腺肿瘤生长。TRF还可以减少乳腺癌向肺部的转移。